Explore the novel technology combining a purified native ECM with the broad-spectrum antimicrobial PHMB.
PuraPly AM is the first purified native ECM with the antimicrobial polyhexamethylene biguanide (PHMB). PuraPly Antimicrobial can be used to manage bioburden and to help control biofilm re-formation while supporting healing across a wide variety of wound types, regardless of severity or duration.1
PuraPly AM is intended for the management of wounds and as an effective barrier to resist microbial colonization within the ECM and reduce microbes penetrating through the ECM.
- Partial- and full-thickness wounds
- Pressure ulcers
- Venous ulcers
- Diabetic ulcers
- Chronic vascular ulcers
- Tunneled/undermined wounds
- Surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence)
- Trauma wounds (abrasions, lacerations, second-degree burns, skin tears)
- Draining wounds
- Purified Type 1 native ECM creates a durable biocompatible scaffold
- Effective barrier against a wide array of microorganisms
- PHMB is known to inhibit the formation of biofilm on the wound surface
BBWM™ is a proactive approach in which all wounds are considered at risk for biofilm. Biofilm is present in virtually all wounds,7-11 is hard to detect, resistant to treatment, and delays wound healing.1-4
Sharp debridement and PuraPly AM are the foundation of BBWM™.1
- Following sharp debridement, biofilm begins to re-form within 24 hours and becomes fully mature within 72 hours2
- A combination of a native ECM and broad-spectrum antimicrobial therapy must be applied immediately following debridement to help prevent biofilm re-formation2
BBWM™ should be considered a critical element of good wound care practices.2-4
- Experts believe that biofilm is present in virtually all wounds,7-11 and that treatment strategies should adjust accordingly3-5
- Suppressing biofilm while managing the other known barriers to wound healing holds the potential to radically advance wound healing3,6
Comprehensive BBWM™ should include antimicrobial products that both control biofilm re-reformation and support healing.4,5
- The ideal antimicrobial product balances a broad antimicrobial spectrum with high tissue compatibility7
- Phillips PL, Wolcott RD, Fletcher J, Schultz GS. Biofilms made easy. Wounds International website. www.woundsinternational.com/made-easys/view/biofilms-made-easy. Published May 17, 2010. Accessed December 20, 2016.
- Wolcott RD, Rumbaugh KP, James G, et al. J Wound Care. 2010;19(8):320-328.
- Wolcott R, Dowd S. Plast Reconstr Surg.2011;127(suppl 1):28S-35S.
- Percival SL, Vuotto C, Donelli G, Lipsky BA. Adv Wound Care (New Rochelle). 2015;4(7):389-397.
- Brantley J, Park H, Sanchez P, Fitzgerald R. Wounds Int. 2016;7(3):1-5.
- Wolcott R, Cutting KF, Ruiz JC. Association for the Advancement of Wound Care. Publication No. UKCT-A0021. 2008:12-17. 7. Müller G, Kramer A. J Antimicrob Chemother.2008;61(6):128-1287.
- Carpenter S et al. WOUNDS. 2016;28(6 Suppl):S1-S20.
- James GA et al. Wound Repair Regen. 2008;16:37-44.
- Malone M et al. J Wound Care. 2017;26(1):20-25.
- Schultz G et al. Wound Repair Regen. 2017;25(5):744-757.
- Donlan RM et al. Clin Microbiol Rev. 2002;15(2):167-193.